Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel antibiotics to treat the serious and life-threatening multidrug-resistant infections that pose a major and growing global health threat. Tetraphase’s proprietary breakthrough chemistry technology enables the design of molecules that can overcome antibiotic resistance. Our drug platform has led to the creation of more than 3,000 broad- and selective-spectrum antibiotic drug candidates. Tetraphase common stock trades under the NASDAQ symbol ‘TTPH.’ Tetraphase is well positioned to be a major player in the multidrug-resistant arena.
Company growth
Type
Public
HQ
Watertown, US
Founded
2006
Size (employees)
69 (est)+26%
Tetraphase Pharmaceuticals was founded in 2006 and is headquartered in Watertown, US

Key People at Tetraphase Pharmaceuticals

Patrick Gage

Patrick Gage

Chairman

Tetraphase Pharmaceuticals Office Locations

Tetraphase Pharmaceuticals has office in Watertown
Watertown, US

Tetraphase Pharmaceuticals Metrics

Tetraphase Pharmaceuticals Summary

Market capitalization

$200 M

Closing share price

$5.34
Tetraphase Pharmaceuticals's current market capitalization is $200 M.

Tetraphase Pharmaceuticals Financials

Tetraphase Pharmaceuticals's revenue is $9.1 M in FY, 2014 which is 50.21% decrease from the previous period.
FY, 2014FY, 2013

Revenue

$9.1 M$18.3 M

Revenue growth, %

-50.2%

Operating income

$-65.8 M$-113 M

Operating expense total

$74.9 M$131 M

Net Income

$-66.7 M$-120 M

Operating cash flow

$18.3 M$103 M

Tetraphase Pharmaceuticals Market Value History

We estimate that Tetraphase Pharmaceuticals's current employees are approximately 6% female and 94% male.

Tetraphase Pharmaceuticals Online Presence

Tetraphase Pharmaceuticals Company Life

You may also be interested in